Evaluation of an assessment tool to guide heart failure support

Not Applicable

Recruiting

• Conditions: Chronic Heart Failure and patient self-care; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12612000558820
• Lead Sponsor: Cardiovascular Research Centre/ Australian Catholic University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-05-25
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

Participants will be 18 years of age or older and have a confirmed diagnosis of CHF. Confirmation of the diagnosis will be from: 1) symptoms and clinical features of congestion that occur at rest or on minimal effort (dyspnoea, orthopnea, paroxysmal nocturnal dyspnoea, fatigue, palpitations, elevated jugular venous pressure, cardiomegaly, lung crepitations, hepatomegaly, oedema); 2) either objective evidence of underlying structural cardiac dysfunction that impairs the ability of the ventricle to fill with or eject blood or an elevated plasma level of B-type natriuretic Peptide (BNP), >200 pg/mL. Participants will have been referred and enrolled into the CHFMP which is conducted across Eastern health.

Exclusion Criteria

Patient participants will be excluded if they reside in a residential aged high care facility (nursing home), have a documented history of moderate-to-severe cognitive impairment or dementia, or have a terminal diagnosis. Participants who do not have sufficient comprehension to read English without the need of a translator will be excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patients in the intervention groups will have significantly higher self-care maintenance, management and confidence scores from the Self-Care Heart Failure Index.[At 3 and 6 months];Patients in the intervention groups will have significantly higher medication adherance scores[At 3 and 6 months]

Secondary Outcome Measures

Name	Time	Method
Health related quality of life (SF-12)[At baseline and at 3 and 6 months post intervention commencement];All-cause hospitalisation and death[At 3 and 6 months post intervention commencement]